drugset / Trial / NCT04835402
Electroporation Potentiated Immunotherapy in Cancer
Phase 2
Unknown
8 enrolled
Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery
Aalborg University · collabDanish Cancer Society · collabOdense University Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The study is investigating the efficacy and safety of combined irreversible electroporation (IRE) and checkpoint inhibition in metastatic pancreatic cancer.
Timeline
- Start
- 2021-05-26
- Primary completion
- 2022-03-07
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |